Inhibition of the AP-1/TFPI2 axis contributes to alleviating cerebral ischemia/reperfusion injury by improving blood–brain barrier integrity
Human Cell · 04.09.2024 · 37 (6) · 1679-1695
DOI: 10.1007/s13577-024-01125-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Cell, online erschienen am 04.09.2024. Verfasst von Yue Cao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China. Hauptthemen laut MEDLINE: Transcription Factor AP-1, Reperfusion Injury, Blood-Brain Barrier, Glycoproteins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Tianjin Key Medical Discipline (Specialty) Construction Project.
Abstract (Originalsprache)
Reperfusion after cerebral ischemia leads to secondary damage to the nervous system, called cerebral ischemia/reperfusion injury (CIRI). The blood-brain barrier (BBB) consists of endothelial cells and tight junction (TJ) proteins, and its disruption aggravates CIRI. Two GSE datasets identified Tissue Factor Pathway Inhibitor 2 (TFPI2) as a differentially upregulated gene (Log2FC > 1, p < 0.01) in the cerebral cortex of ischemic rats, and TFPI2 affects angiogenesis of endothelial cells. Moreover, genes (c-Jun, c-Fos, FosL1) encoding subunits of Activator Protein-1 (AP-1), a transcription factor involved in IRI, were highly expressed in ischemic samples. Thus, the effects of the AP-1/TFPI2 axis on CIRI were explored. We determined increased TFPI2 expression in the cerebral cortex of rats receiving middle cerebral artery occlusion (MCAO) for 90 min and reperfusion (R) for 48 h. Then AAV2-shTFPI2 particles (5 × 1010 vg) were injected into the right lateral ventricle of rats 3 weeks before MCAO/R. TFPI2 knockdown decreased infarct size and neuronal injury in ischemic rats. It improved BBB integrity, demonstrated by reduced FITC-dextran leakage in brain tissues of MCAO/R-operated rats. Furthermore, it increased the expression of TJ proteins (Occludin, Claudin-5, TJP-1) in the cerebral cortex of rats with CIRI. Consistently, we found that TFPI2 knockdown mitigated cell damage in mouse endothelial bEND.3 cells with oxygen and glucose deprivation (ODG) for 6 h and reoxygenation (R) for 18 h (OGD/R) treatment. High co-expression of c-Jun and c-Fos significantly elevated TFPI2 promoter activity. c-Jun knockdown inhibited TFPI2 expression in OGD/R-treated bEND.3 cell. Collectively, our findings demonstrate that inhibition of the AP-1/TFPI2 axis alleviates CIRI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China.
- Department of Neurology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, People's Republic of China.
- Department of Neurology, The Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China. lixinsci@126.com.
Förderung
- Tianjin Key Medical Discipline (Specialty) Construction Project
Zitieren
APA
Cao, Y., Xing, R., Li, Q., Bai, Y., Liu, X., Tian, B., & Li, X. (2024). Inhibition of the AP-1/TFPI2 axis contributes to alleviating cerebral ischemia/reperfusion injury by improving blood–brain barrier integrity. Human Cell, 37(6), 1679-1695. https://doi.org/10.1007/s13577-024-01125-3
Vancouver
Cao Y, Xing R, Li Q, Bai Y, Liu X, Tian B, et al. Inhibition of the AP-1/TFPI2 axis contributes to alleviating cerebral ischemia/reperfusion injury by improving blood–brain barrier integrity. Human Cell. 2024;37(6):1679-1695. doi:10.1007/s13577-024-01125-3
BibTeX
@article{Cao2024,
author = {Cao, Yue and Xing, Ruixian and Li, Qiushi and Bai, Yang and Liu, Xuewen and Tian, Buxian and Li, Xin},
title = {Inhibition of the AP-1/TFPI2 axis contributes to alleviating cerebral ischemia/reperfusion injury by improving blood–brain barrier integrity},
journal = {Human Cell},
year = {2024},
volume = {37},
number = {6},
pages = {1679--1695},
doi = {10.1007/s13577-024-01125-3}
}
EUVIMED